What does Clinical Research Vanackere do?

Clinical Research Vanackere is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Private Limited, started on 9 June 2016, 1 establishment.

What is the address of Clinical Research Vanackere?

The registered office of Clinical Research Vanackere is located at Kriebekestraat 1B, 3390 Tielt-Winge.

Is Clinical Research Vanackere still active?

Yes. According to the CBE (18 September 2026) Clinical Research Vanackere is active, legal situation “Normale toestand”, started on 9 June 2016.

Is Clinical Research Vanackere registered on Peppol?

Yes, Clinical Research Vanackere is registered on the Peppol network with ID 0208:0656693859.

What is the enterprise number of Clinical Research Vanackere?

The enterprise number of Clinical Research Vanackere is BE0656693859.

When was Clinical Research Vanackere founded?

Clinical Research Vanackere was founded on 9 June 2016.

Who are the directors of Clinical Research Vanackere?

According to the 2025 annual accounts, the directors of Clinical Research Vanackere are: Birgit Vanackere.

Is Clinical Research Vanackere a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 June 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Clinical Research Vanackere make in 2025?

Clinical Research Vanackere posted a profit after taxes of € 45,633 in financial year 2025.

What is the revenue of Clinical Research Vanackere?

As a small company, Clinical Research Vanackere is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 89,440.

Clinical Research Vanackere (Private Limited)

Dossier Clinical Research Vanackere, printed on 18 September 2026 from databakkes.be/en/0656693859/clinical-research-vanackere. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Clinical Research Vanackere from Tielt-Winge, company number BE0656693859, closed financial year 2025 with a result of € 45,633 after tax. For that financial year Clinical Research Vanackere recorded a gross margin of € 89,440 and equity of € 180,771. Compared with financial year 2024, the result moved from € 16,645 to € 45,633. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.

What it is worth Growing

€ 180,771

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 45,633

▲ 174% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 174,571.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 41,927

▼ 31% vs 2024

Of which on lease € 33,697.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 66,393

▼ 26% vs 2024

€ 34,107 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 1,188

▼ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 15,576

▲ € 14,034 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 32,934 Gross margin 2022: € 32,934 First fiscal year in the series	€ 54,054 Gross margin 2023: € 54,054 ▲ 64% vs 2022 (€ 32,934) Favourable step	€ 50,777 Gross margin 2024: € 50,777 ▼ 6% vs 2023 (€ 54,054) Unfavourable step	€ 89,440 Gross margin 2025: € 89,440 ▲ 76% vs 2024 (€ 50,777) Favourable step	▲ 76%
Profit after taxes	€ 19,648 Profit after taxes 2022: € 19,648 First fiscal year in the series	€ 22,622 Profit after taxes 2023: € 22,622 ▲ 15% vs 2022 (€ 19,648) Favourable step	€ 16,645 Profit after taxes 2024: € 16,645 ▼ 26% vs 2023 (€ 22,622) Unfavourable step	€ 45,633 Profit after taxes 2025: € 45,633 ▲ 174% vs 2024 (€ 16,645) Favourable step	▲ 174%
Equity	€ 143,120 Equity 2022: € 143,120 First fiscal year in the series	€ 151,232 Equity 2023: € 151,232 ▲ 6% vs 2022 (€ 143,120) Favourable step	€ 135,137 Equity 2024: € 135,137 ▼ 11% vs 2023 (€ 151,232) Unfavourable step	€ 180,771 Equity 2025: € 180,771 ▲ 34% vs 2024 (€ 135,137) Favourable step	▲ 34%
Total debts	€ 55,942 Total debts 2022: € 55,942 First fiscal year in the series	€ 80,698 Total debts 2023: € 80,698 ▲ 44% vs 2022 (€ 55,942) Unfavourable step	€ 95,753 Total debts 2024: € 95,753 ▲ 19% vs 2023 (€ 80,698) Unfavourable step	€ 83,156 Total debts 2025: € 83,156 ▼ 13% vs 2024 (€ 95,753) Favourable step	▼ 13%
Cash	€ 8,194 Cash 2022: € 8,194 First fiscal year in the series	€ 1,006 Cash 2023: € 1,006 ▼ 88% vs 2022 (€ 8,194) Unfavourable step	€ 0 Cash 2024: € 0 ▼ 100% vs 2023 (€ 1,006) Unfavourable step	-
Retained profit	€ 136,920 Retained profit 2022: € 136,920 First fiscal year in the series	€ 145,032 Retained profit 2023: € 145,032 ▲ 6% vs 2022 (€ 136,920) Favourable step	€ 128,937 Retained profit 2024: € 128,937 ▼ 11% vs 2023 (€ 145,032) Unfavourable step	€ 174,571 Retained profit 2025: € 174,571 ▲ 35% vs 2024 (€ 128,937) Favourable step	▲ 35%
Dividend	€ 6,655 Dividend 2022: € 6,655 First fiscal year in the series	€ 14,510 Dividend 2023: € 14,510 ▲ 118% vs 2022 (€ 6,655) Unchanged	€ 32,740 Dividend 2024: € 32,740 ▲ 126% vs 2023 (€ 14,510) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 32,740) Unchanged	▼ 100%
Bank debt	€ 36,099 Bank debt 2022: € 36,099 First fiscal year in the series	€ 75,600 Bank debt 2023: € 75,600 ▲ 109% vs 2022 (€ 36,099) Unfavourable step	€ 89,811 Bank debt 2024: € 89,811 ▲ 19% vs 2023 (€ 75,600) Unfavourable step	€ 66,393 Bank debt 2025: € 66,393 ▼ 26% vs 2024 (€ 89,811) Favourable step	▼ 26%
Balance sheet total	€ 199,063 Balance sheet total 2022: € 199,063 First fiscal year in the series	€ 231,931 Balance sheet total 2023: € 231,931 ▲ 17% vs 2022 (€ 199,063) Unchanged	€ 230,891 Balance sheet total 2024: € 230,891 Unchanged (€ 231,931) Unchanged	€ 263,927 Balance sheet total 2025: € 263,927 ▲ 14% vs 2024 (€ 230,891) Unchanged	▲ 14%

Key figures of Clinical Research Vanackere, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Clinical Research Vanackere?

What happened at Clinical Research Vanackere in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 25, 2026 New annual accounts for financial year 2025: profit of € 45,633 (▲ 174% vs 2024). Source: NBB ↗
Jun 9, 2016 New establishment in Tielt-Winge. KBO
2016 Birgit Vanackere became a director. NBB
Jun 9, 2016 Start of the company according to the CBE. KBO

In short

From € 19,648 profit in 2022 to € 45,633 profit in 2025.

Paid € 47,461 in corporate taxes since 2022.

Best year ever: 2025, with € 45,633 profit.

Paid out € 53,905 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Clinical Research Vanackere? We notify you, reason included.

Follow Clinical Research Vanackere

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Birgit Vanackere

Clinical Research Vanackere

Behind Clinical Research Vanackere is Birgit Vanackere.

See the full network in the app

Directors

According to the 2025 annual accounts

Birgit Vanackere

Director

since 2016

Establishments

Establishment units

Physical locations of this company

Registered office

Kriebekestraat 1B

3390 Tielt-Winge

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0656.693.859

VAT number

BE 0656.693.859

Registered office

Kriebekestraat 1B, 3390 Tielt-Winge

Names & denominations

Clinical Research Vanackere · CRV

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 June 2016

Peppol

Active · Active since 11 Feb 2025

Activities · NACE

Vervaardiging van farmaceutische grondstoffen

Activiteiten van holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Markt- en opinieonderzoek

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Holdings

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗